Catalent (Novo Holdings) vs Northway Biotech: CDMO Comparison
Side-by-side comparison of Catalent (Novo Holdings) and Northway Biotech on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Catalent (Novo Holdings) has FDA inspections on record (1); Northway Biotech does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Northway Biotech holds 8 active EMA GMP certificates; Catalent (Novo Holdings) does not appear in EudraGMDP.
On a 13-modality CDMO landscape, both Catalent (Novo Holdings) and Northway Biotech qualify as AAV manufacturers; Northway Biotech carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both Catalent (Novo Holdings) and Northway Biotech qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: Catalent (Novo Holdings) vs Northway Biotech
Which has the stronger FDA inspection record, Catalent (Novo Holdings) or Northway Biotech?
Both Catalent (Novo Holdings) and Northway Biotech maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Catalent (Novo Holdings) has 1 FDA inspection on record; Northway Biotech has 0.
How do Catalent (Novo Holdings) and Northway Biotech compare on European GMP coverage?
Catalent (Novo Holdings) holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Northway Biotech holds 8 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for AAV manufacturing — Catalent (Novo Holdings) or Northway Biotech?
Both Catalent (Novo Holdings) and Northway Biotech are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Catalent (Novo Holdings) carries a Signal Score of 75/100 and Northway Biotech carries 81/100 — a small lead for Northway Biotech. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →